Feds Say They Are Out of Options to Improve 340B Transparency and Ask Congress to Take Action

Drug Industry Daily
A A
Any major changes to the way the 340B drug discount program is regulated and overseen will require action from Congress, experts told a House subcommittee Tuesday.

To View This Article:

Login

Subscribe To Drug Industry Daily